Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants
@article{Weir2018InfluenceOR, title={Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants}, author={M. Weir and R. Kreutz}, journal={Mayo Clinic Proceedings}, year={2018}, volume={93}, pages={1503–1519} }
Abstract With the growing integration of non–vitamin K antagonist oral anticoagulants (NOACs) into clinical practice, questions have arisen regarding their use in special populations, including groups that may have been underrepresented in clinical trials. Patients with renal impairment, particularly in the lower echelons of renal function, are one such group. In an effort to elucidate the current evidence regarding the use of NOACs in patients with renal impairment, a systematic assessment of… CONTINUE READING
4 Citations
Use of New Oral Anticoagulants / Direct Oral Anticoagulants in Malignant Patients
- Medicine
- Cureus
- 2020
- 5
- PDF
Dose discordance of direct acting oral anticoagulants using different equations for estimating GFR: a literature review
- Medicine
- Expert review of clinical pharmacology
- 2020
Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel
- Medicine
- CJC open
- 2020
Concomitant diabetes with atrial fibrillation and anticoagulation management considerations
- Medicine
- European heart journal supplements : journal of the European Society of Cardiology
- 2020
- PDF
References
SHOWING 1-10 OF 97 REFERENCES
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
- Medicine
- Journal of clinical pharmacology
- 2016
- 101
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
- Medicine
- Clinical pharmacokinetics
- 2010
- 670
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
- Medicine
- British journal of clinical pharmacology
- 2010
- 350
- Highly Influential
Dose-finding study of rivaroxaban in hemodialysis patients.
- Medicine
- American journal of kidney diseases : the official journal of the National Kidney Foundation
- 2015
- 82
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
- Medicine
- Thrombosis and haemostasis
- 2015
- 98
- PDF
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery
- Medicine
- Clinical pharmacokinetics
- 2008
- 218
Pipe Dreams About Apixaban for Stroke Prevention in Renal Impairment
- Medicine
- Journal of clinical pharmacology
- 2016
- 6
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
- Medicine
- Clinical Pharmacokinetics
- 2015
- 92
- PDF
Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation
- Medicine
- European Journal of Clinical Pharmacology
- 2014
- 45
Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study
- Medicine
- Journal of clinical pharmacology
- 2015
- 29